B · Normal
[WuXi Juno denies "making a profit at a loss": opening up space for volume at a price with a profit basis] On November 16, reporters learned that WuXi Juno's price reduction of CAR-T drugs into the basic medical insurance catalog was a "cry at a loss". The relevant management of WuXi Juno recently denied the statement and said that this is a prudent decision and "opens up space for volume at a price with a profit basis". After entering the medical insurance, WuXi Juno is very confident to gradually promote the company to achieve profitability. In terms of production capacity arrangements, the company estimates that the current production capacity can basically meet the market demand in 2027, and the company is also making preparations for further expansion of production. Xiaocai's note: WuXi Junuo-B announced yesterday evening that the medical insurance payment standard for the company's CAR-T product Benoda® (Richia Oronza Injection) is 288,600 yuan, effective from January 1, 2027. Management predicts that domestic substitution and scale effects will drive the unit production cost of this product to continue to drop by more than 65%. (Reporter Wang Junxian)
🕐 2026-11-16 10:26

Comments

0/500
Captcha (click to refresh)
No comments yet